Diagnostic challenges in drug-induced liver injury

Affiliations

¹ Division of Hepatology and Nutrition, Office of New Drugs, Food and Drug Administration, Silver Spring, Maryland, USA.
² Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Paul H Hayashi et al. Clin Liver Dis (Hoboken). 2024.

. 2024 May 31;23(1):e0206.

doi: 10.1097/CLD.0000000000000206. eCollection 2024 Jan-Jun.

¹ Division of Hepatology and Nutrition, Office of New Drugs, Food and Drug Administration, Silver Spring, Maryland, USA.
² Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.

No abstract available

Conflict of interest statement

The authors have no conflicts to report.

1. LiverTox®. https://www.ncbi.nlm.nih.gov/books/NBK547852/
1. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of International Consensus Meetings: Application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–30. - PubMed
1. Hayashi PH, Lucena MI, Fontana RJ, Bjornsson ES, Aithal GP, Barnhart H, et al. . A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022;76:18–31. - PMC - PubMed
1. Nathwani RA, Kumar SR, Reynolds TB, Kaplowitz N. Marked elevation in serum transaminases: An atypical presentation of choledocholithiasis. Am J Gastroenterol. 2005;100:295–8. - PubMed
1. Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, et al. . Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology. 2010;51:2040–8. - PubMed